Truist Financial Corp significantly increased its stake in Rocket Companies (NYSE:RKT) by 291.9% in the fourth quarter, purchasing an additional 82,873 shares to reach a total of 111,265 shares valued at $2.15 million. Despite this acquisition and Rocket Companies beating first-quarter earnings expectations, the stock has recently fallen by 6.6% to $13.82, trading well below its 52-week high. Analysts currently maintain a consensus "Hold" rating for RKT with a price target of $20.93.

Truist Financial Corp decreased its stake in Ciena Corporation by 15.4% in the fourth quarter, holding 9,559 shares valued at $2.24 million. Despite insider selling totaling $17.4 million, Ciena reported strong quarterly results with $1.35 EPS on $1.43 billion in revenue, surpassing analyst estimates. The company maintains a "Moderate Buy" consensus rating among analysts with an average target price of $367.56.

Argus has raised its price target for First Solar (NASDAQ: FSLR) to $275 from $250, maintaining a buy rating. This upgrade follows the company's strong first-quarter 2026 earnings, which surpassed analyst expectations with an EPS of $3.22 and revenue of $1.04 billion. Despite the positive outlook from Argus, analyst sentiment on First Solar remains mixed, with other firms issuing various ratings and price targets.

Moody's has assigned its top AAA-mf rating to tokenized money market funds offered by Fidelity and BlackRock, affirming their high credit quality, liquidity, and capital preservation. Fidelity's FILQ fund, launched on May 6, utilizes Sygnum's tokenization platform with infrastructure support from JPMorgan Chase, Apex Group, and Chainlink. BlackRock's BUIDL fund, introduced in March 2024, is noted as one of the largest tokenized Treasury funds, contributing to the broader tokenized U.S. government debt market's growth to over $15 billion in assets under management.

Stryker Corp is highlighted as a leading medical technology company, innovating in orthopedics, medsurg, and neurotechnology. The article emphasizes its strong market presence in the US, with a significant revenue base from US hospitals. Stryker's robust financial performance in Q1 2026, driven by its diversified product portfolio and strategic acquisitions, positions it well within the growing global medical devices market.

US Bancorp's shares dropped 3.2% to $52.74 on May 13, 2026, extending a 6.1% weekly decline despite the bank topping Q4 CY2025 earnings estimates with revenue of $7.37 billion and EPS of $1.26. The financial services company, a major US holding company operating in banking, investment, mortgage, trust, and payment services, saw its revenue increase by 5.1% year-over-year. Investors are watching for sustained growth in upcoming quarters amidst economic uncertainties.

Revvity has received FDA clearance for its total testosterone automated chemiluminescence immunoassay (ChLIA) through its Immunodiagnostic Systems (IDS) subsidiary. This new assay, alongside existing tests for free testosterone and sex hormone-binding globulin (SHBG), offers a fully integrated diagnostic approach for testosterone-related disorders on a single platform. This advancement aims to streamline workflow and centralize diagnostics for identifying suspected hypogonadism in men, replacing complex legacy methods.

SK Bioscience Co Ltd significantly expanded its partnership with Sanofi in December 2024 to develop and commercialize pneumococcal vaccines, strengthening its position in the global biotech and vaccine markets. This collaboration, along with strong Q1 2026 provisional results, highlights the company's growth potential and its relevance for US investors seeking exposure to international biotech innovations. SK Bioscience focuses on vaccine R&D and manufacturing, leveraging advanced platforms and strategic alliances to address global health needs.

This article provides market data for the Global X Defense Tech ETF (Derivatives) with the ticker SHLD. It lists current prices, 24-hour changes, highs, lows, and trading volumes from various exchanges, specifically mentioning OKX Futures and MEXC Futures. The content appears to be a snapshot from a cryptocurrency market data platform.

SIM Acquisition Corp. I (Nasdaq: SIMA, SIMAW) announced that its shareholders approved an extension to the business combination deadline until July 12, 2027, from the original July 11, 2026. This decision followed an extraordinary general meeting where a substantial 22,447,232 public shares were redeemed at approximately $10.79 per share, leaving only 552,768 public shares outstanding. The company also converted all 4,666,667 Class B Ordinary Shares into Class A Ordinary Shares, impacting ownership and potentially increasing share price volatility due to the reduced public float.